Screening of Spider Venom Peptides and Molecular Docking of FLT3 and LCK
₹ 300.00
Screening of Spider Venom Peptides and Molecular Docking of FLT3 and LCK
Durgesh M. Agase
Bulletin of Pure and Applied Sciences
Zoology (Animal Science), Vol.42A, No.1,
January-June 2023: P.149-156
DOI: 10.48165/bpas.2023.42A.1.13
Original Research Article
Description
Description
Screening of Spider Venom Peptides and Molecular Docking of FLT3 and LCK
Durgesh M. Agase
| Author’s Affiliation:
Assistant Professor, Department of Zoology, Govt Jatashankar Trivedi College, Balaghat, Madhya Pradesh 481101, India
|
| *Corresponding author:
Dr. Durgesh M. Agase, Assistant Professor, Department of Zoology, Govt Jatashankar Trivedi College, Balaghat, Madhya Pradesh 481101, India E-mail: sbt.durgesh@gmail.com Article Info: Received on 27.02.2023 Revised on 05.05.2023 Approved on 19.05.2023 Accepted on 26.05.2023 Published on 16.06.2023
|
Abstract
ABSTRACT:
The drawbacks of traditional chemotherapy include its inability to dissolve in water, lack of selectivity, and multidrug resistance. The use of anticancer peptides is a unique therapeutic approach against cancer cells. In this In-silico work, the kinase inhibition activity for both chosen target molecules (Flt3 and Lck protein) was evaluated in order to find a possible anti-leukemic spider venom peptide. Out of the 11 spider venom peptides, Lycosin-I peptide (from Lycosa singoriensis) for Lck and Latarcin 2a peptide (from Lachesana tarabaevi) for Flt3 were suggested as the best lead peptides for the creation of anti-leukemic drugs.
Keywords: Anticancer Peptides, Chemotherapy, Spider Venom
